Effect of erythropoietin-stimulating agent on uremic inflammation

Yuri Tanaka, Nobuhiko Joki, Hiroki Hase, Masaki Iwasaki, Masato Ikeda, Ryoichi Ando, Toshio Shinoda, Daijo Inaguma, Toshifumi Sakaguchi, Yasuhiro Komatsu, Fumihiko Koiwa, Toshihiko Yamaka, Takashi Shigematsu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The goal of the present study was to explore the effect of medications that are commonly prescribed for CKD patients on uremic state. Methods: This was a cross-sectional study. From January 2006 to October 2009, 1,623 patients with end-stage kidney disease (ESKD) commenced hemodialysis (HD) at the 9 participating hospitals. The criteria for exclusion from the database were 1) serum C-reactive protein (CRP) >3 mg/dL, 2) WBC count >9,000/mm3 or <4,000/mm3, and 3) patients with cancer, immune complex disease, or vasculitis. A total of 900 patients were entered into the final database. We explored the association of serum CRP just before the first HD session with clinical characteristics, laboratory data, and medications for CKD in the predialysis period. Results: On univariate analysis, age, CTR, eGFR, and WBC were significantly correlated with CRP. Systolic and diastolic blood pressure, serum albumin, LDL-C, HDL-C, Hb, Cr, and Ca were inversely associated with CRP. Use of erythropoietin-stimulating agents (ESA) using (r = ?0.111, p = 0.0015), renin-angiotensin-aldosterone system inhibitors (r = ?0.083, p = 0.0154), and calcium channel blockers (r = ?0.1, p = 0.0039) was also negatively correlated with CRP. However, only use of ESA showed a significant negative correlation with CRP that was independent of other clinical factors and CKD medications on multiple regression analysis. Conclusion: ESA may strongly reduce uremic inflammation in addition to improving anemia. To confirm this potential effect, a large-scale longitudinal study would be required.

Original languageEnglish
Article number17
JournalJournal of Inflammation (United Kingdom)
Volume9
DOIs
Publication statusPublished - 15-05-2012

Fingerprint

Erythropoietin
C-Reactive Protein
Inflammation
Renal Dialysis
Blood Proteins
Immune Complex Diseases
Databases
Blood Pressure
Blood pressure
Angiotensins
Calcium Channel Blockers
Renin-Angiotensin System
Vasculitis
Antigen-Antibody Complex
Aldosterone
Renin
Regression analysis
Serum Albumin
Chronic Kidney Failure
Longitudinal Studies

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Cell Biology

Cite this

Tanaka, Y., Joki, N., Hase, H., Iwasaki, M., Ikeda, M., Ando, R., ... Shigematsu, T. (2012). Effect of erythropoietin-stimulating agent on uremic inflammation. Journal of Inflammation (United Kingdom), 9, [17]. https://doi.org/10.1186/1476-9255-9-17
Tanaka, Yuri ; Joki, Nobuhiko ; Hase, Hiroki ; Iwasaki, Masaki ; Ikeda, Masato ; Ando, Ryoichi ; Shinoda, Toshio ; Inaguma, Daijo ; Sakaguchi, Toshifumi ; Komatsu, Yasuhiro ; Koiwa, Fumihiko ; Yamaka, Toshihiko ; Shigematsu, Takashi. / Effect of erythropoietin-stimulating agent on uremic inflammation. In: Journal of Inflammation (United Kingdom). 2012 ; Vol. 9.
@article{f775019e30cd40789fca02c69f25f845,
title = "Effect of erythropoietin-stimulating agent on uremic inflammation",
abstract = "Background: The goal of the present study was to explore the effect of medications that are commonly prescribed for CKD patients on uremic state. Methods: This was a cross-sectional study. From January 2006 to October 2009, 1,623 patients with end-stage kidney disease (ESKD) commenced hemodialysis (HD) at the 9 participating hospitals. The criteria for exclusion from the database were 1) serum C-reactive protein (CRP) >3 mg/dL, 2) WBC count >9,000/mm3 or <4,000/mm3, and 3) patients with cancer, immune complex disease, or vasculitis. A total of 900 patients were entered into the final database. We explored the association of serum CRP just before the first HD session with clinical characteristics, laboratory data, and medications for CKD in the predialysis period. Results: On univariate analysis, age, CTR, eGFR, and WBC were significantly correlated with CRP. Systolic and diastolic blood pressure, serum albumin, LDL-C, HDL-C, Hb, Cr, and Ca were inversely associated with CRP. Use of erythropoietin-stimulating agents (ESA) using (r = ?0.111, p = 0.0015), renin-angiotensin-aldosterone system inhibitors (r = ?0.083, p = 0.0154), and calcium channel blockers (r = ?0.1, p = 0.0039) was also negatively correlated with CRP. However, only use of ESA showed a significant negative correlation with CRP that was independent of other clinical factors and CKD medications on multiple regression analysis. Conclusion: ESA may strongly reduce uremic inflammation in addition to improving anemia. To confirm this potential effect, a large-scale longitudinal study would be required.",
author = "Yuri Tanaka and Nobuhiko Joki and Hiroki Hase and Masaki Iwasaki and Masato Ikeda and Ryoichi Ando and Toshio Shinoda and Daijo Inaguma and Toshifumi Sakaguchi and Yasuhiro Komatsu and Fumihiko Koiwa and Toshihiko Yamaka and Takashi Shigematsu",
year = "2012",
month = "5",
day = "15",
doi = "10.1186/1476-9255-9-17",
language = "English",
volume = "9",
journal = "Journal of Inflammation",
issn = "1476-9255",
publisher = "Springer Nature",

}

Tanaka, Y, Joki, N, Hase, H, Iwasaki, M, Ikeda, M, Ando, R, Shinoda, T, Inaguma, D, Sakaguchi, T, Komatsu, Y, Koiwa, F, Yamaka, T & Shigematsu, T 2012, 'Effect of erythropoietin-stimulating agent on uremic inflammation', Journal of Inflammation (United Kingdom), vol. 9, 17. https://doi.org/10.1186/1476-9255-9-17

Effect of erythropoietin-stimulating agent on uremic inflammation. / Tanaka, Yuri; Joki, Nobuhiko; Hase, Hiroki; Iwasaki, Masaki; Ikeda, Masato; Ando, Ryoichi; Shinoda, Toshio; Inaguma, Daijo; Sakaguchi, Toshifumi; Komatsu, Yasuhiro; Koiwa, Fumihiko; Yamaka, Toshihiko; Shigematsu, Takashi.

In: Journal of Inflammation (United Kingdom), Vol. 9, 17, 15.05.2012.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of erythropoietin-stimulating agent on uremic inflammation

AU - Tanaka, Yuri

AU - Joki, Nobuhiko

AU - Hase, Hiroki

AU - Iwasaki, Masaki

AU - Ikeda, Masato

AU - Ando, Ryoichi

AU - Shinoda, Toshio

AU - Inaguma, Daijo

AU - Sakaguchi, Toshifumi

AU - Komatsu, Yasuhiro

AU - Koiwa, Fumihiko

AU - Yamaka, Toshihiko

AU - Shigematsu, Takashi

PY - 2012/5/15

Y1 - 2012/5/15

N2 - Background: The goal of the present study was to explore the effect of medications that are commonly prescribed for CKD patients on uremic state. Methods: This was a cross-sectional study. From January 2006 to October 2009, 1,623 patients with end-stage kidney disease (ESKD) commenced hemodialysis (HD) at the 9 participating hospitals. The criteria for exclusion from the database were 1) serum C-reactive protein (CRP) >3 mg/dL, 2) WBC count >9,000/mm3 or <4,000/mm3, and 3) patients with cancer, immune complex disease, or vasculitis. A total of 900 patients were entered into the final database. We explored the association of serum CRP just before the first HD session with clinical characteristics, laboratory data, and medications for CKD in the predialysis period. Results: On univariate analysis, age, CTR, eGFR, and WBC were significantly correlated with CRP. Systolic and diastolic blood pressure, serum albumin, LDL-C, HDL-C, Hb, Cr, and Ca were inversely associated with CRP. Use of erythropoietin-stimulating agents (ESA) using (r = ?0.111, p = 0.0015), renin-angiotensin-aldosterone system inhibitors (r = ?0.083, p = 0.0154), and calcium channel blockers (r = ?0.1, p = 0.0039) was also negatively correlated with CRP. However, only use of ESA showed a significant negative correlation with CRP that was independent of other clinical factors and CKD medications on multiple regression analysis. Conclusion: ESA may strongly reduce uremic inflammation in addition to improving anemia. To confirm this potential effect, a large-scale longitudinal study would be required.

AB - Background: The goal of the present study was to explore the effect of medications that are commonly prescribed for CKD patients on uremic state. Methods: This was a cross-sectional study. From January 2006 to October 2009, 1,623 patients with end-stage kidney disease (ESKD) commenced hemodialysis (HD) at the 9 participating hospitals. The criteria for exclusion from the database were 1) serum C-reactive protein (CRP) >3 mg/dL, 2) WBC count >9,000/mm3 or <4,000/mm3, and 3) patients with cancer, immune complex disease, or vasculitis. A total of 900 patients were entered into the final database. We explored the association of serum CRP just before the first HD session with clinical characteristics, laboratory data, and medications for CKD in the predialysis period. Results: On univariate analysis, age, CTR, eGFR, and WBC were significantly correlated with CRP. Systolic and diastolic blood pressure, serum albumin, LDL-C, HDL-C, Hb, Cr, and Ca were inversely associated with CRP. Use of erythropoietin-stimulating agents (ESA) using (r = ?0.111, p = 0.0015), renin-angiotensin-aldosterone system inhibitors (r = ?0.083, p = 0.0154), and calcium channel blockers (r = ?0.1, p = 0.0039) was also negatively correlated with CRP. However, only use of ESA showed a significant negative correlation with CRP that was independent of other clinical factors and CKD medications on multiple regression analysis. Conclusion: ESA may strongly reduce uremic inflammation in addition to improving anemia. To confirm this potential effect, a large-scale longitudinal study would be required.

UR - http://www.scopus.com/inward/record.url?scp=84860805137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860805137&partnerID=8YFLogxK

U2 - 10.1186/1476-9255-9-17

DO - 10.1186/1476-9255-9-17

M3 - Article

VL - 9

JO - Journal of Inflammation

JF - Journal of Inflammation

SN - 1476-9255

M1 - 17

ER -